Cary Street Partners Asset Management’s AbbVie ABBV Stock Holding History

Cary Street Partners Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.89M	Buy	24,742 +71	+0.3%	+$13.3K	0.64%	40
2024 Q2	$4.23M	Buy	24,671 +908	+4%	+$150K	0.62%	38
2024 Q1	$4.33M	Buy	23,763 +118	+0.5%	+$20.3K	0.67%	39
2023 Q4	$3.66M	Sell	23,645 -1,080	-4%	-$157K	0.63%	44
2023 Q3	$3.69M	Sell	24,725 -541	-2%	-$79.4K	0.69%	42
2023 Q2	$3.4M	Sell	25,266 -334	-1%	-$49K	0.63%	43
2023 Q1	$4.08M	Sell	25,600 -720	-3%	-$110K	0.77%	35
2022 Q4	$4.25M	Buy	26,320 +591	+2%	+$90.6K	0.86%	30
2022 Q3	$3.45M	Sell	25,729 -3,010	-10%	-$432K	0.83%	29
2022 Q2	$4.4M	Sell	28,739 -12,176	-30%	-$1.86M	1.03%	26
2022 Q1	$6.63M	Buy	40,915 +427	+1%	+$62K	1.32%	16
2021 Q4	$5.48M	Sell	40,488 -7,390	-15%	-$873K	1.17%	25
2021 Q3	$5.17M	Sell	47,878 -1,293	-3%	-$148K	1.82%	16
2021 Q2	$5.54M	Sell	49,171 -206,538	-81%	-$23.3M	1.32%	20
2021 Q1	$5.72M	Buy	255,709 +8,837	+4%	+$945K	1.41%	14
2020 Q4	$5.63M	Buy	+246,872	New	+$23.7M	1.66%	6

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cary Street Partners Asset Management's ABBV Position: Q3 2024 in Review

Cary Street Partners Asset Management increased its AbbVie (ABBV) stake by 0.29% in Q3 2024, buying an estimated $13.3K and bringing the position to 24,742 shares worth $4.89M. The position accounts for 0.64% of the portfolio, ranked #40.

Cary Street Partners Asset Management first reported a position in ABBV in Q4 2020 and has held it in 16 quarters since. The position peaked at $6.63M in Q1 2022. 3,499 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Cary Street Partners Asset Management held 24,742 shares of AbbVie worth $4.89M as of Q3 2024.
Cary Street Partners Asset Management bought 71 AbbVie shares in Q3 2024, an estimated $13.3K.
AbbVie made up 0.64% of Cary Street Partners Asset Management's portfolio in Q3 2024, its #40 holding.
Cary Street Partners Asset Management first reported a position in AbbVie in Q4 2020 and has held it in 16 quarters since.
Cary Street Partners Asset Management's AbbVie position peaked at $6.63M in Q1 2022.
3,499 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Cary Street Partners Asset Management's 13F filing for Q3 2024, filed 30 Oct 2024.